ERBB2 and neoplasm: The potential molecular mechanisms underlying the reduction in tumor growth may involve decreased expression of ErbB2 and ErbB3, as well as the inhibition of the cell cycle regulator cytosolic protein D. The findings indicate that enhancing the intestinal enrichment of B. polyfermentans could yield synergistic antitumor effects when combined with RTK-targeted therapies (Ma et al. 2010).